NASDAQ:JNCE - Jounce Therapeutics Stock Price, Price Target & More

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics (NASDAQ:JNCE) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The business earned $11.20 million during the quarter, compared to analyst estimates of $13.33 million. Jounce Therapeutics had a negative return on equity of 19.90% and a negative net margin of 47.73%. View Jounce Therapeutics' Earnings History.

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Jounce Therapeutics.

5 brokerages have issued 12-month target prices for Jounce Therapeutics' stock. Their predictions range from $13.00 to $35.00. On average, they expect Jounce Therapeutics' share price to reach $23.75 in the next year. View Analyst Ratings for Jounce Therapeutics.

Some companies that are related to Jounce Therapeutics include DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Solid Biosciences (SLDB), Heska (HSKA), Novavax (NVAX), CASI Pharmaceuticals (CASI), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX) and Fate Therapeutics (FATE).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

News articles about JNCE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a news impact score of 0.01 on Accern's scale. They also assigned media coverage about the company an impact score of 44.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (3.64%), BlackRock Inc. (3.52%), Omega Fund Management LLC (1.63%), venBio Select Advisor LLC (1.61%), Citadel Advisors LLC (0.90%) and Fosun International Ltd (0.49%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Spark Investment Management LLC, Omega Fund Management LLC, Parsons Capital Management Inc. RI, Parsons Capital Management Inc. RI, BlackRock Inc., Russell Investments Group Ltd. and Northern Trust Corp. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

JNCE stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Citadel Advisors LLC, Redmile Group LLC, Elephas Investment Management Ltd, Dimensional Fund Advisors LP, A.R.T. Advisors LLC, JBF Capital Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $10.60.

Jounce Therapeutics has a market capitalization of $369.34 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.